biologics Flashcards
hydrocortisone glucocorticoid/mineralocorticoid activity
duration
high glucocorticoid, some mineralocorticoid
short-acting
dexamethasone glucocorticoid/mineralocorticoid activity
duration
some gluco, no mineralo
long acting
fludrocortisone glucocorticoid/mineralocorticoid activity
duration
no gluco, very high mineralo
long-acting
prednisone/methylprednisolone gluco/mineral
duration
moderate, moderate
intermediate-acting
glucocorticoid AEs
poorly tolerated
hyperglycemia leukocytosis HPA axis insufficiency neuropsych effects osteopenia myopathy fluid retention gastritis
conventional synthetic DMARD examples & uses
methotrexate, leflunomide, sulfasalazine, hydroxychloroquine
RA
methotrexate uses
RA - first line, once weekly
IBD
conventional synthetic DMARDS AE
ALL - folic acid deficiency, bone marrow suppression, infection, hepatitis, teratogenic
methotrexate - stomatitis **folic acid supplementation reduces toxicity
lefluonomide - alopecia ** loooong half life
sulfasalazine - rash, SJS **avoid in pt w sulfa allergy
hydroxychloroquine use
used in RA for pt that are pregnant
hydroxychloroquine AE
ocular toxicitieies, increased skin pigmentation, QT PROLONGATION
JAK inhibitor AEs
infection, malignancy, THROMBOSIS, HLD
jak inhibitors examples
tofacitinib
baracitinib
upadacitinib
biologic meds characteristics
produced by living cell cultures large, complex, heavy molecules complex structures potentially immunogenic unstable and sensitive to external conditions
-mab medications
monoclonal antibodies
-cept medications
soluble receptor antagonist
etanercept
biologics rule of thumb
update immunizations and screen before tx
avoid live vaccines
injectables (not oral!)
do not combine biologics
injection site rxn
IV infusion rxn
antidrug antibody formation
TNF-a inhibitors
etanercept infliximab adalimumab golimumab certolizumab pegol
infliximab admin
give w methotrexate in RA
give w azathioprine or 6-mercantopurine in IBD
golimumab admin
give w methotrexate in RA
certolizumab pegol admin
give w polyethylene glycol to prolong half life and reduce immunogenicity
TNF-a inhibitor AEs
HEART FAILURE!!!
malignancy, infection, anti-drug antibody formation (immunogenicity)
CD20 monoclonal antibodies AEs
infusion/injection site rxn - premedicate w antihistamine/APAP/glucocorticoid
malignancy
infection (leukoencephalopathy)
fumaric acids indications
MS
fumaric acids AE
gi upset/flushing
infections, pymphopenia
S1PR modulators use
MS
S1PR AEs
QT prolongation bradyarrhythmia HTN macular edema infection
CI in pt w hx of severe cardiac problem in past 6 mos
S1PR modulators examples
fingolimod - higher incidence of QTprolong/brady - admin in clinc
siponimod
ozanimod
induction immunosuppressants
glucocorticoids
basiliximab
antithymocyte immune globulin
alemtuzumab
maintenance immunosuppression
calcineurin inhibitor, antiproliferative, glucocorticoid
tacro > cyclosporine
mycophenolate > azathioprine
prednisone
cyclosporine/tacro AEs
nephrotox, tremor, HTN, HLD, hyperglc, gingival hyperplasia, hirsutism
tacro - hyperuricemia
titrated, many interax
mycophenolate/azathioprine AE
bone marrow suppression
myco - diarrhea
azathioprine - hepatotox - varied metabolism TMPT
RA mgmt
methotrexate
contraindication to methotrexate - leflunomide, sulfasalazine
short term glucocorticoids when initiating/changing csDMARDs
try another DMAD, then use bDMARD or tsDMARD
types of MS
relapse-remitting - clearly defined relapses w full recovery or residual deficit upon recovery
secondary progressive - RRMS w steady deterioration of function
primary progressive - occasional plateaus w steady decline
MS therapy efficacy
infusion therapy
oral therapy
injection therapy
relapse remitting tx
any meds
poor prognosis - natalizumab, ocrelizumab, alemtuzumab
secondary progressive MS tx
siponimod
or any DMT
PPMS tx
oreclizumab